Molecular Partners
Latest round
- Series B
Last raised
- Dec 2009
Total raised
- $61M
Investors
- 5
About Molecular Partners
Molecular Partners AG specializes in biopharmaceuticals, primarily working with DARPin technology to create targeted therapies.75 mn on June 16, 2021.Molecular Partners specializes in pioneering DARPin (Designed Ankyrin Repeat Protein) therapeutics aimed at providing innovative solutions for cancer treatment. Their core product offerings include a range of tetra-specific T cell engagers that target multiple cancer-specific antigens, such as CD33, CD123, and CD70, in conjunction with CD3 to enhance T cell activity against tumors. The company also features a lead program targeting DLL3, as well as a logic-gated platform designed for the targeted and conditional activation of immune cells. These products are designed to address critical unmet needs in oncology, particularly for patients with forms of cancer that are resistant to conventional therapies.10 for the same year. The company generates revenue primarily through strategic partnerships and collaborations with pharmaceutical companies and research institutions that seek to leverage its proprietary DARPin technology for drug development. Transaction structures typically involve joint development agreements, where partners finance research and clinical trials in exchange for access to specific therapeutic candidates. Revenue may also be derived from milestone payments linked to the achievement of regulatory approvals or sales targets, as well as royalties on commercialized products. The focus on collaborations suggests a business model emphasizing B2B relationships, providing tailored therapeutics to oncology-focused enterprises.Molecular Partners plans to continue its growth trajectory by launching new products designed around its DARPin technology. Specific timelines for product launches have not been disclosed.75 mn from the public offering in June 2021 to support these initiatives.
Who invested in Molecular Partners
5 investors across 2 rounds
See all investors in Molecular Partners
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Molecular Partners
Who invested in Molecular Partners?
Molecular Partners has 5 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Molecular Partners raised?
Molecular Partners has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Molecular Partners last raise money?
Molecular Partners's most recent round on record is a Series B, in Dec 2009.
What does Molecular Partners do?
Molecular Partners AG specializes in biopharmaceuticals, primarily working with DARPin technology to create targeted therapies.
Where is Molecular Partners headquartered?
Molecular Partners is headquartered in Zurich, Switzerland.
Which VCs invest in companies like Molecular Partners?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at Molecular Partners's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Molecular Partners? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.